摘要
192例脑卒中后抑郁焦虑患者随机数字表法分为观察组和对照组，各96例，观察组采用舒肝解郁胶囊联合帕罗西汀治疗，对照组采用帕罗西汀治疗。治疗2、6周时，观察组17项汉密尔顿抑郁量表（HAMD）、汉密尔顿焦虑量表（HAMA）评分为（22±5）与（13±3）分、（9±4）与（5±3）分，低于对照组的（24±3）与（14±4）分、（12±5）与（8±4）分（均P〈0．05）；治疗6周，观察组HAMD、HAMA减分率、神经功能康复各量表评分优于对照组（均P〈0．05）。舒肝解郁胶囊联合帕罗西汀治疗脑卒中后患者抑郁焦虑，起效快、安全，疗效肯定，能加速肢体功能康复。
A total of 192 poststroke patients with depression and anxiety were assigned randomly into study group （n = 96 ） and control group （n = 96）. The study group received both capsules Shugan-jieyu and paroxetine while the control group paroxetine alone. Compared with the control group, scores of both Hamilton depression scale （HAMD） and Hamilton anxiety scale （HAMA） were significantly different at the end of week 2 and 6 in the study group （P 〈 O. 05）. The HAMD and HAMA deduction rate and the scores of mangled extremity severity, mini-mental state examination and modified Barthel index at the end of week 6 of the study group were better than those of the control group （ all P 〈 O. 05 ）. The combined use of capsules Shugan-jieyu and paroxetine could improve symptoms of depression and anxiety, offer a higher safety and accelerate the rehabilitation of extremity function.
出处
《中华全科医师杂志》
2013年第6期483-485,共3页
Chinese Journal of General Practitioners
基金
新疆维吾尔自治区卫生厅青年科技人才专项科研项目（2009Y05）
乌鲁木齐市科学技术计划项目（Y101310009）
关键词
脑卒中后抑郁焦虑
舒肝解郁
Poststroke depression and anxiety
Shugan-jieyu
